JAK inhibitors

eczema skin condition
Biotech

Lynk’s JAK1 inhibitor improves severity, itching in eczema study

Lynk seems to have safely removed itself from EQRx’s wreckage, as its eczema asset improved area and severity in a phase 2 clinical trial.   
Gabrielle Masson Aug 9, 2023 12:35pm
boxing punch blow hit punching bag fight

Theravance takes another blow, cuts staff again in regroup

Feb 28, 2023 4:31am
FDA

Concert persuades FDA to keep alopecia therapy breakthrough tag

Feb 15, 2023 10:00am
GSK

ASH: GSK explores new avenues for JAK drug from $1.9B Sierra buy

Dec 11, 2022 5:30pm
On target clinical trial success bullseye score

Nimbus posts psoriasis data on rival to Bristol Myers' Sotyktu

Nov 30, 2022 6:00am
arena hockey game play referee hockey sticks penalty

Pfizer's Arena goal? Get out of the way

May 24, 2022 6:45am